CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma.
Anupam KumarEsraa MohamedSchuyler TongKatharine ChenJoydeep MukherjeeYunita LimCynthia M WongZoe BoosalisAnny ShaiRussell O PieperNalin GuptaArie PerryAndrew W BollenAnnette M MolinaroDavid A SolomonJoseph T C ShiehJoanna J PhillipsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
We identify the MAPK-activated lower grade astrocytoma PXA as having an immune-rich tumor microenvironment and suggest this tumor may be particularly vulnerable to immunotherapeutic modulation. We also identify CXCL14 as an important determinant of the glioma-associated immune microenvironment, sufficient to promote an antitumor CD8+ T-cell response.